AKT1 and Hepatic steatosis: In vitro, Ang-(1–7)/ACE2 ameliorated hepatic steatosis, oxidative stress and inflammation in free fatty acid (FFA)-induced HepG2 cells and what’s more, Akt inhibitors reduced ACE2-mediated lipid metabolism.